Allogene療法 ALLO 深 滬
已收盤 02-06 16:00:00 美东时间
1.69
+0.060
+3.68%
華盛通- 最 高1.75
- 今 開1.66
- 成交量 396.08万股
- 最 低 1.63
- 昨 收 1.63
- 總市值 3.80亿
- 52周最高 3.78
- 市盈率 靜 --
- 換手率 1.76%
- 52周最低 0.8621
- 委 比 60.24%
- 總股本 2.25亿
- 歷史最高 55.00
- 量 比 0.43
- 振 幅 7.36%
- 歷史最低 0.8621
- 每 手 1
- 風險率 0.28%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Allogene Therapeutics SVP and CTO Benjamin Machinas Beneski Reports Sale of Common Shares
Allogene Therapeutics SVP and CTO Benjamin Machinas Beneski Reports Sale of Common Shares Benjamin Machinas Beneski, Senior Vice President and Chief Technical Officer of Allogene Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link
02-05 06:21
美股牛股 | 德克斯户外涨近20%，财报表现优异；磷化铟公司AXTI涨超13%
TechCreate Group Ltd. Class A涨100.1%；阿诺医药涨62.8%；罗致恒富涨27.8%
01-31 10:13
Cellectis Announces 2026 Strategy and Catalysts
Cellectis outlines its 2026 strategic priorities, focusing on advancing allogeneic CAR-T therapies. Key catalysts include interim data for lasme-cel in r/r B-ALL from the pivotal Phase 2 BALLI-01 trial, Phase 1 data for eti-cel in r/r NHL, and leveraging partnerships with AstraZeneca, Servier/Allogene, and Iovance. Lasme-cel Phase 1 results show 68% ORR and favorable safety, while eti-cel demonstrates 88% ORR in Phase 1. The company expects to pr...
01-08 21:30
美股大行评级 | 瑞银上调美光科技目标价从300美元升至400美元；Freedom上调百度目标价从120美元升至160美元
今日重点评级关注：Needham：维持Vaxcyte"买入"评级，目标价从90美元升至110美元；Citizens: 维持LGI Homes"跑赢大市"评级，目标价从85美元升至95美元
01-08 18:33
UBS Initiates Coverage On Allogene Therapeutics with Buy Rating, Announces Price Target of $8
UBS analyst Michael Yee initiates coverage on Allogene Therapeutics (NASDAQ:ALLO) with a Buy rating and announces Price Target of $8.
01-08 04:16
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers XTL Biopharmaceuticals (NASDAQ:XTLB) shares moved upwards by 9.3% to $...
2025-12-24 05:05
Allogene Arbitration Victory Pressures Cellectis Shares Tuesday
Cellectis shares fell after Allogene cited a favorable arbitration ruling confirming control of cema-cel and outlining key CAR-T milestones.
2025-12-17 02:09
Cellectis Announces Arbitral Decision in Dispute with Servier
Cellectis announced that the Arbitral Tribunal has partially terminated the License Agreement with Servier regarding UCART19 V1 (ALLO-501), requiring Cellectis to engage in good-faith discussions for a direct license at Allogene's request. All other claims were dismissed. Cellectis is a biotechnology company developing cell and gene therapies using its gene-editing platform. More information is available on their website.
2025-12-15 21:51
CytoMed Therapeutics Enters Into MOU With UMMC To Establish Phase I Clinical Trial To Investigate Safety And Efficacy Of CytoMed's Patented Allogeneic Unmodified Gamma Delta T Cells For No-Option Cancer Patients In Malaysia
CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or the "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable
2025-12-08 21:08
Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit
Indaptus Therapeutics' Dr. Michael Newman will present at the 3rd Donor Selection & Cell Source Summit in San Diego. His talk will focus on the Company's Decoy bacterial platform, which aims to address donor cell variability in allogeneic immune cell cancer therapy. Decoy20, the lead candidate, uses killed bacteria to trigger a broad immune response, enhancing the quality and consistency of immune cell products. Newman highlighted preclinical dat...
2025-11-17 13:00
